Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
KERX's Cash to Debt is ranked higher than
87% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. KERX: No Debt )
KERX' s 10-Year Cash to Debt Range
Min: No Debt   Max: No Debt
Current: No Debt

Interest Coverage No Debt
KERX's Interest Coverage is ranked higher than
76% of the 484 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 76.05 vs. KERX: No Debt )
KERX' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: 35.30
M-Score: -3.26
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -696.65
KERX's Operating margin (%) is ranked lower than
54% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.55 vs. KERX: -696.65 )
KERX' s 10-Year Operating margin (%) Range
Min: -15010.67   Max: 38.97
Current: -696.65

-15010.67
38.97
Net-margin (%) -692.63
KERX's Net-margin (%) is ranked lower than
54% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.99 vs. KERX: -692.63 )
KERX' s 10-Year Net-margin (%) Range
Min: -13813.48   Max: 41.62
Current: -692.63

-13813.48
41.62
ROE (%) -55.72
KERX's ROE (%) is ranked lower than
52% of the 796 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. KERX: -55.72 )
KERX' s 10-Year ROE (%) Range
Min: -216.51   Max: 32.67
Current: -55.72

-216.51
32.67
ROA (%) -48.47
KERX's ROA (%) is ranked lower than
53% of the 809 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.01 vs. KERX: -48.47 )
KERX' s 10-Year ROA (%) Range
Min: -409.52   Max: 25.69
Current: -48.47

-409.52
25.69
ROC (Joel Greenblatt) (%) -6647.42
KERX's ROC (Joel Greenblatt) (%) is ranked lower than
54% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.22 vs. KERX: -6647.42 )
KERX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -48355.36   Max: 10444.68
Current: -6647.42

-48355.36
10444.68
EBITDA Growth (%) 17.20
KERX's EBITDA Growth (%) is ranked higher than
83% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. KERX: 17.20 )
KERX' s 10-Year EBITDA Growth (%) Range
Min: -45.1   Max: 71.3
Current: 17.2

-45.1
71.3
EPS Growth (%) 18.30
KERX's EPS Growth (%) is ranked higher than
82% of the 624 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. KERX: 18.30 )
KERX' s 10-Year EPS Growth (%) Range
Min: -44.5   Max: 60
Current: 18.3

-44.5
60
» KERX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

KERX Guru Trades in Q3 2013

Jim Simons 991,100 sh (New)
» More
Q4 2013

KERX Guru Trades in Q4 2013

Jim Simons Sold Out
» More
Q1 2014

KERX Guru Trades in Q1 2014

Pioneer Investments 284,299 sh (New)
Seth Klarman 6,310,850 sh (New)
Jim Simons 18,700 sh (New)
Steven Cohen 1,525,058 sh (New)
» More
Q2 2014

KERX Guru Trades in Q2 2014

Seth Klarman 10,539,986 sh (+67.01%)
Steven Cohen 1,247,000 sh (unchged)
Jim Simons Sold Out
Pioneer Investments Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with KERX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Seth Klarman 2014-06-30 Add 67.01%1.04%$12.11 - $17.03 $ 13.64-4%10539986
Seth Klarman 2014-03-31 New Buy2.6%$12.16 - $16.88 $ 13.64-9%6310850
John Burbank 2012-12-31 Sold Out 0.06%$2.31 - $3.14 $ 13.64402%0
John Burbank 2012-09-30 New Buy0.06%$1.79 - $2.83 $ 13.64556%500000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Keryx Biopharmaceuticals Inc

Seth Klarman’s The Baupost Group Buys eBay, SunEdison Semiconductor, Keryx Biopharmaceuticals, Sells BP, Theravance
Legendary value investor, hedge fund manager Seth Klarman (Trades, Portfolio) just reported his second quarter portfolio. Seth Klarman (Trades, Portfolio) buys eBay Inc, SunEdison Semiconductor Ltd, Keryx Biopharmaceuticals Inc, Kosmos Energy Ltd, Boyd Gaming Corporation, Triquint Semiconductor, RF Micro Devices Inc, Cheniere Energy Inc, Viasat Inc, Veritiv Corp, Veritiv Corp, sells BP PLC, Theravance Inc during the 3-months ended 06/30/2014, according to the most recent filings of his investment company, The Baupost Group. As of 06/30/2014, The Baupost Group owns 24 stocks with a total value of $6.1 billion. These are the details of the buys and sells. Read more...
Baupost’s Seth Klarman Takes 10% Stake in Keryx Biopharmaceuticals
The Baupost Group’s Seth Klarman (Trades, Portfolio) has purchased a new holding that constitutes more than 5% of the company, requiring reporting during the quarter and appearing on GuruFocus RealTime Picks. The purchase was of 9,151,600 shares of Keryx Biopharmaceuticals (KERX), which represents 10.07% of the company’s shares outstanding. Read more...
Weekly Insider Sells Highlight: KERX, ORCL, QCOM, GILD
According to GuruFocus Insider Data, the largest insider sells during the past week were: Keryx Biopharmaceuticals Inc., Oracle Corporation, Qualcomm Inc. and Gilead Sciences Inc. Read more...
Weekly Insider Sells Highlight: FLT, KERX, KOG, MEI, HTZ
According to GuruFocus Insider Data, the top insider sells for the past week were: Fleetcor Technologies Inc., Keryx Biopharmaceuticals Inc., Kodiak Oil & Gas Corp., Methode Electronics Inc. and Hertz Global Holdings Inc. Read more...

Ratios

vs
industry
vs
history
P/B 10.00
KERX's P/B is ranked higher than
52% of the 828 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. KERX: 10.00 )
KERX' s 10-Year P/B Range
Min: 0.46   Max: 49
Current: 10

0.46
49
EV-to-EBIT -15.90
KERX's EV-to-EBIT is ranked higher than
52% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 31.14 vs. KERX: -15.90 )
KERX' s 10-Year EV-to-EBIT Range
Min: 2.8   Max: 22.2
Current: -15.9

2.8
22.2
Current Ratio 7.47
KERX's Current Ratio is ranked higher than
91% of the 650 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.46 vs. KERX: 7.47 )
KERX' s 10-Year Current Ratio Range
Min: 1.88   Max: 106.93
Current: 7.47

1.88
106.93
Quick Ratio 7.47
KERX's Quick Ratio is ranked higher than
92% of the 650 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. KERX: 7.47 )
KERX' s 10-Year Quick Ratio Range
Min: 1.88   Max: 106.93
Current: 7.47

1.88
106.93

Valuation & Return

vs
industry
vs
history
Price/Net Cash 10.71
KERX's Price/Net Cash is ranked higher than
92% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. KERX: 10.71 )
KERX' s 10-Year Price/Net Cash Range
Min: 1.09   Max: 29.11
Current: 10.71

1.09
29.11
Price/Net Current Asset Value 10.63
KERX's Price/Net Current Asset Value is ranked higher than
89% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. KERX: 10.63 )
KERX' s 10-Year Price/Net Current Asset Value Range
Min: 1.07   Max: 29.11
Current: 10.63

1.07
29.11
Price/Tangible Book 10.47
KERX's Price/Tangible Book is ranked higher than
59% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.11 vs. KERX: 10.47 )
KERX' s 10-Year Price/Tangible Book Range
Min: 0.93   Max: 26.2
Current: 10.47

0.93
26.2
Forward Rate of Return (Yacktman) -1.69
KERX's Forward Rate of Return (Yacktman) is ranked higher than
65% of the 664 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.93 vs. KERX: -1.69 )
KERX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -121.4   Max: -17
Current: -1.69

-121.4
-17

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:KYX.Germany
Keryx Biopharmaceuticals, Inc is a Delaware corporation incorporated in Delaware in October 1998. The Company is a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. The company is developing ZerenexTM (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes. Zerenex is also in Phase 2 development in the U.S. for the management of phosphorus and iron deficiency in anemic patients with Stages 3 to 5 non-dialysis dependent CKD. It is also engage in business development activities that include seeking strategic relationships for Zerenex, as well as evaluating compounds and companies for in-licensing or acquisition. Its only drug candidate is Zerenex. It may engage in business development activities that include seeking strategic relationships for Zerenex, as well as evaluating compounds and companies for in-licensing or acquisition. Its competitors include pharmaceutical companies and biotechnology companies, as well as universities and public and private research institutions.
» More Articles for KERX

Headlines

Articles On GuruFocus.com
Seth Klarman’s The Baupost Group Buys eBay, SunEdison Semiconductor, Keryx Biopharmaceuticals, Sel Aug 14 2014 
Seth Klarman Tops Guru Scoreboard for First Half 2014 Jul 05 2014 
Baupost’s Seth Klarman Takes 10% Stake in Keryx Biopharmaceuticals May 12 2014 
Weekly Insider Sells Highlight: KERX, ORCL, QCOM, GILD Mar 24 2014 
Weekly Insider Sells Highlight: FLT, KERX, KOG, MEI, HTZ Jan 06 2014 
comment on KERX Mar 02 2013 
Can Keryx Succeed Without Partnership? Apr 24 2012 
Keryx Still Has High Potential from Zerenex Apr 12 2012 
Bio drug Nov 03 2011 
comment on KERX Oct 26 2011 


More From Other Websites
Insider Trading Alert - DVA, DATA And KERX Traded By Insiders Sep 11 2014
Keryx Falls after Ferric Citrate's Approval with Warnings Sep 08 2014
Keryx CEO says FDA warning label for drug is 'grossly misunderstood' Sep 08 2014
[$$] Keryx's FDA Approval a Mixed Bag Sep 08 2014
Why Keryx Biopharmaceuticals (KERX) Stock Is Falling Today Sep 08 2014
Keryx Biopharmaceuticals (KERX) Crumbles: Stock Falls by 5.5% Sep 08 2014
Keryx Bear Case Bolstered by Less-Than-Zippy 'Zerenex' Label Sep 08 2014
BUZZ-U.S. Stocks on the Move-Keryx, GlaxoSmithKline, Astrazeneca Sep 08 2014
Keryx Biopharma downgraded by FBR Capital Sep 08 2014
Correction: Keryx-Drug Approval story Sep 06 2014
Correction: Keryx-Drug Approval story Sep 06 2014
Warnings Issued for Keryx Dialysis Drug Sep 05 2014
FDA approves Keryx's kidney drug with warnings, shares fall Sep 05 2014
KERYX BIOPHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 05 2014
Keryx Biopharmaceuticals, Inc. to Present at the Rodman & Renshaw 16th Annual Global Investment... Sep 05 2014
Keryx Finds Out That Not All FDA Approvals Are Great Wins Sep 05 2014
Infoblox Inc. (BLOX) Climbs On Earnings Sep 05 2014
Keryx Biopharmaceuticals Inc Conference Call to discuss the approval of Ferric Citrate scheduled for... Sep 05 2014
Keryx Biopharma gets U.S. approval for kidney drug Sep 05 2014
Keryx Biopharmaceuticals Receives FDA Approval of Ferric Citrate, a New, Oral Iron-Based Treatment... Sep 05 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK